This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Still Bullish on BioMarin, Lexicon Pharma

NEW YORK ( TheStreet) -- An update on BioMarin Pharmaceuticals (BMRN - Get Report) and Lexicon Pharmaceuticals (LXRX - Get Report), two biopharma stocks that I own and have written about recently for TheStreet

BioMarin shares are up almost 30% since Monday's announcement that the phase III trial of GALNS for the treatment of MPS IV or Morquio syndrome met its primary endpoint of change in six-minute walk compared to placebo when dose weekly. Key secondary efficacy endpoints in the study were also met.

These GALNS results are definitely a huge positive and should help BioMarin get the drug approved easily. An FDA filing is expected in the first quarter of 2013, which means approval could come by the end of next year.

In late September, I said the GALNS study was the most important event in BioMarin's history because the MPS IV patient population is bigger than both the MPS I and MPS II populations treated by drugs the company already sells. GALNS has the potential to double BioMarin's revenue. I also predicted the study's success.

Keep in mind that Biomarin still has a robust pipeline beyond GALNS. Peg-Pal for PKU will begin phase III trials in the first half of next year. BMN-701 will report phase 1b data early next year. A phase 2 trial for BMN-111 in treating dwarfism should also begin next year.

Biomarin is the longest-tenured stock in my SharkBiotech portfolio. It's nice to see patience rewarded.

On a conference call Tuesday, Lexicon management said partnering discussions for its diabetes drug LX4211 are moving forward well, discussions are robust and they expect to announce a partner before beginning phase III trials next year.

As a reminder, diabetes is quickly becoming an epidemic in this country and Big Pharma is eager to find new ways of treating this disease . LX4211 is unique in that it targets two different transporters of glucose SLGT-1 and SLG-2, which makes it unique in the new class of SLGT inhibitors.

The phase II data on LX4211 were outstanding and Lexicon should have no problem lining up a partner sooner rather than later

Lexicon shares are 25% in the last few weeks but I believe the current stock price is attractive for adding ahead of a possible partnership.

Rosenblum is long BioMarin and Lexicon.
Dan Rosenblum has been a full-time stock trader since 1999 after leaving a job at a publicly held medical-device company. Rosenblum joined that year and has been the online trading community's resident biotech expert ever since. Rosenblum writes the newsletter, which has outperformed the S&P 500 and the Nasdaq Biotechnology Index every year since its inception in 2006. Rosenblum lives with his wife and kids in Rockland County, New York.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMRN $103.50 2.80%
LXRX $11.44 -1.70%
AAPL $111.38 1.70%
FB $92.91 0.48%
GOOG $642.67 0.55%


Chart of I:DJI
DOW 17,053.39 +2.64 0.02%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,820.3650 +9.5770 0.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs